Machine Learning Tool for New Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitors.

Journal: Molecules (Basel, Switzerland)
PMID:

Abstract

Depression, a serious mood disorder, affects about 5% of the population. Currently, there are two groups of antidepressants that are the first-line treatment for depressive disorder: selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. The aim of the study was to develop Quantitative Structure-Activity Relationship (QSAR) models for serotonin (SERT) and norepinephrine (NET) transporters to predict the affinity and inhibition potential of new molecules. Models were developed using the Automated Machine Learning tool Mljar based on 80% of the dataset according to 10-fold cross-validation and externally validated on the remaining 20% of data. The molecular representation featured two-dimensional Mordred descriptors. For each model, Shapley additive explanations analysis was performed to clarify the influence of the descriptors on the models' predictions. Based on the final QSAR models, the following results were obtained: NET and pIC50 value RMSE = 0.678, R = 0.640; NET and pKi RMSE = 0.590, R = 0.709; SERT and pIC50 RMSE = 0.645, R = 0.678; SERT and pKi value RMSE = 0.540, R = 0.828. QSAR models for serotonin and norepinephrine transporters have been made available in a new module of the SerotoninAI application to enhance usability for scientists.

Authors

  • Natalia Łapińska
    Department of Pharmaceutical Technology and Biopharmaceutics, Jagiellonian University Medical College, 30-688 Kraków, Poland.
  • Jakub Szlęk
    Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.
  • Adam Pacławski
    Department of Pharmaceutical Technology and Biopharmaceutics, Jagiellonian University Medical College, Medyczna 9 St, 30-688 Kraków, Poland.
  • Aleksander Mendyk
    Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.